Cabergoline (CAB) is a new dopaminergic ergot derivative that has been shown to induce sustained prolactin (PRL) inhibition in animals and humans. The aim of our study was to investigate the effectiveness of CAB in the treatment of patients with microprolactinoma. CAB was orally administered to nine subjects for 12 months at a dose of 0.5 mg/week. All patients underwent high-resolution computed tomographic (CT) scan of the pituitary fossa before and after treatment. Blood samples were collected monthly and four weeks after the end of treatment to evaluate PRL levels. PRL levels significantly (p<0.01) decreased in most of the patients by the second week of treatment and reached normal values (range 5 to 25 ng/mL) within four to eight weeks. Normal serum PRL levels (mean 17.5 θ 8.7 ng/mL) were achieved in eight patients (89%) by the end of the trial. Four subjects (44%) had partial resistance to therapy and three required higher cabergoline dose (1 to 1.5 mg/week) to normalize PRL serum values. Despite higher doses, one patient's PRL values ramained slightly above normal (33 ng/mL) for the duration of therapy. CAB was well tolerated by all women. Our results show that CAB is very effective in lowering PRL levels in patients with micropro-lactinoma, and its appears to be appropriate for long-term therapy.
|Number of pages||7|
|Journal||Advances in Therapy|
|Publication status||Published - 1989|
ASJC Scopus subject areas